Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials.
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsClinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells.Asthma pharmacogenetics and the development of genetic profiles for personalized medicineThe relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population.Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes.Long-acting beta-agonists and the risk of intensive care unit admission in children.Pragmatic research and outcomes in asthma and COPDAdverse effects of salmeterol in asthma: a neuronal perspective.Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist.Pharmacotherapy of asthma: regular treatment or on demand?Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicineOnce-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids.Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies.Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.Safe use of long-acting β-agonists: what have we learnt?Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Beta-Adrenergic AgonistsSafety of long-acting beta-agonists: urgent need to clear the air remains.Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.Long-acting beta-agonists and asthma death: how useful are different study designs to evaluate the potential association?The β2 -adrenoceptor agonist terbutaline recovers rat pharyngeal dilator muscle force decline during severe hypoxia.Use and safety of long-acting β2-agonists for pediatric asthma
P2860
Q22305858-5B0414D2-7844-4593-A543-F337DC908605Q24199079-08F89545-6208-498D-A365-7101E4725ED0Q33792699-89844635-0A5B-41F6-8C81-1E8868AC5DEDQ34492011-932612CA-770C-44F8-9560-1CD78BBF53EBQ35076452-02873E90-5A5E-4D03-834F-3BE23BB2718EQ35923040-F37F6304-D964-4E49-A97C-A2614776D5FAQ36160624-2704A8C4-AC60-47D7-BB19-8C62D11F7EC1Q36912259-1672CC59-953E-43B7-8DF8-259D7BF3CC1BQ37300877-884ACAB8-FCAA-4057-A93F-5AE8F446A681Q37314867-14861B71-D5A7-48DA-AF3C-329DC6E99521Q37425660-BE566240-8022-4CE2-B41B-EA9A3DBDCC53Q37462963-FDB16E47-AD7C-4514-B241-EDC48D5FC071Q37578103-9D14D9BE-EEFB-4412-BF64-6FA740EE5F48Q37600573-04890A62-C511-4BFE-97BB-EB7A5250A596Q37658668-313937CD-5CB9-4EC6-AAEB-ABB9A416413AQ37729297-1F224885-A29E-4DEF-9EE2-ACF096F870F6Q37735203-0F226AE6-6CCC-40BD-A4C0-6C6CDFCD8F8BQ37763188-11C31804-0F59-43C4-921C-697183F16CBEQ37763189-2ED4EE4C-C151-4010-8F87-583A6F2C4BC6Q37869146-2DCDE2F0-5E3B-4362-B975-14C89BD239E9Q38196942-CC2FE050-2A28-400F-B26E-FF80966D0C64Q38248438-A4358A89-75E3-4C5D-8FC4-214161D33904Q38974241-9CF8E1D5-D3CC-4D4F-A8BA-6A75BE5BE161Q42845071-F724DBCA-C79E-4C09-9EED-5C7C85C3E269Q42917507-8EC94186-2FD3-4B61-BCAE-31E062DFB84AQ43042737-60775B05-DDB0-4005-A433-B10786F57E6BQ48113838-5EAA3B3C-BA86-4758-B6C1-78B1B53E65DDQ57821604-4DC51EA5-2FD0-447C-A7EB-D5CB296E3C9E
P2860
Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@ast
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@en
type
label
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@ast
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@en
prefLabel
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@ast
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@en
P2093
P1476
Long-acting beta-agonists: a r ...... a from asthma clinical trials.
@en
P2093
P356
10.1183/09031936.00145006
P577
2008-09-03T00:00:00Z